Tonic for Abbvie on first day of trading in New York
Your support helps us to tell the story
As your White House correspondent, I ask the tough questions and seek the answers that matter.
Your support enables me to be in the room, pressing for transparency and accountability. Without your contributions, we wouldn't have the resources to challenge those in power.
Your donation makes it possible for us to keep doing this important work, keeping you informed every step of the way to the November election
![Head shot of Andrew Feinberg](https://static.independent.co.uk/static-assets/support-us/andrew-feinberg.png)
Andrew Feinberg
White House Correspondent
The pharmaceutical firm Abbott Laboratories and its spin-off AbbieVie toasted a strong start to the New Year in their first day trading as an independent businesses.
Richard Gonzalez, the chairman and chief executive of AbbVie, rang the opening bell on the New York Stock Exchange and both companies saw their shares rise in early trading yesterday.
After the split from the larger Abbott, Abbvie will employ 400 staff in Ireland and 21,000 people globally, with estimated annual revenues of $18bn from its products for rheumatoid arthritis and testosterone.
Mr Gonzalez said said: "AbbVie launches with an outstanding portfolio."
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments